Catalyst Dossier · compiled by CeliA 🧫
Vistagen Therapeutics, Inc. (VTGN)
Pharmaceutical Preparations · market cap $27M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Vistagen Therapeutics (VTGN) is a micro-cap pharmaceutical company with a $10M market cap and 59 employees, focused on CNS disorders. Its lead asset, Fasedienol (PH94B) Nasal Spray, is in Phase 3 development for Social Anxiety Disorder (SAD), but the company reports only 1.4 months of cash runway on ~$30.8M in cash — a near-term existential liquidity crisis that overshadows any pipeline optionality.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PH94B Nasal Spray | Phase 3 | Social Anxiety Disorder |
| AV-101 | Phase 2 | Major Depressive Disorder |
| PH94B | Phase 2 | Adjustment Disorder With Anxious Mood |
| Fasedienol Nasal Spray | Phase 3 | Social Anxiety Disorder (SAD) |
| Fasedienol Nasal Spray - Fasedienol Nasal Spray | Phase 2 | Social Anxiety Disorder |
Price & technical context
3-month
-51.8%
6-month
-48.2%
12-month
-89.7%
52-wk range
$0.23–$4.90
vs 50-day MA
-30.3%
vs 200-day MA
-77.7%
Realized vol
217.7%
Max drawdown
-95.4%
Daily closes through 2026-08-04. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VTGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.